Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Prostatic Neoplasms 10Glioblastoma 10Oropharyngeal Neoplasms 7Rectal Neoplasms 6Neoplasms 6Lung Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Urinary Bladder Neoplasms 4Burkitt Lymphoma 4Adenocarcinoma of Lung 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Lymphoma, Follicular 3Hodgkin Disease 3Gliosarcoma 3Glioma 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma 3Triple Negative Breast Neoplasms 2Sarcoma 2Rhabdomyosarcoma 2Neoplasm, Residual 2Mesothelioma, Malignant 2Meningeal Carcinomatosis 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

sapanisertib 1pertuzumab 1Trastuzumab 1Radiotherapy 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Neoplasms × Radiotherapy × 30 days × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡